Travere Therapeutics, Inc. · NASDAQ:TVTX

Heerma Peter sold 283,189 Travere Therapeutics, Inc. shares (Form 4)

Traded Sep 15 to Sep 17, 2026 · Filed Sep 17, 2026

From Sep 15 to Sep 17, 2026, Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 283,189 Travere Therapeutics, Inc. shares at an average US$63.06 for US$17.9M under a trading plan, leaving 117,066 shares. Filed Sep 17, 2026 (Form 4).

Sold
283,189 shares
Price
US$63.06 average (US$62.05 to US$65.31)
Value
US$17.9M
Holding after
117,066 shares
Trading plan
Yes (Made under a plan set in advance)
Role
EVP, CHIEF COMMERCIAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 15, 2026Common StockOption exercise39,283US$26.88181,349Direct
Sep 15, 2026Common StockOption exercise1,381US$22.40182,730Direct
Sep 15, 2026Common StockOption exercise36,526US$8.93219,256Direct
Sep 15, 2026Common StockSale71,938US$62.05147,318Direct
Sep 15, 2026Common StockSale27,421US$62.59119,897Direct
Sep 15, 2026Common StockSale1,400US$63.65118,497Direct
Sep 15, 2026Common StockSale1,431US$65.31117,066Direct
Sep 16, 2026Common StockOption exercise100,000US$11.25217,066Direct
Sep 16, 2026Common StockOption exercise55,000US$15.46272,066Direct
Sep 16, 2026Common StockOption exercise17,717US$26.88289,783Direct
Sep 16, 2026Common StockSale93,604US$63.25196,179Direct
Sep 16, 2026Common StockSale79,113US$63.65117,066Direct
Sep 17, 2026Common StockOption exercise8,282US$22.40125,348Direct
Sep 17, 2026Common StockSale8,282US$65.07117,066Direct

Source

View original at SEC

Related